Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.

BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time ...

The U.S. Senate Banking Committee voted Thursday to advance President Donald Trump's nominees to lead the Securities and Exchange Commission and the Office of the Comptroller of the Currency.

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...

Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...

US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a ...

San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...

PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...

Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a ...

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) announced positive new data from studies of VOXZOGO in children with achondroplasia and in ongoing clinical trials investigating other skeletal ...